Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Gordon James who wrote (429)	12/5/1999 10:50:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 666

Gordon, Thanks for the informed commentary from ASH. Did the letters "BLA" cross the lips of the people at the CLTR booth by any chance? Have you had a chance to visit the IDEC people? Be interested to see if they too have any updated Rit+CHOP data. Looking at the disclosed side effects of CHOP and the Rit+CHOP study, it would seem to me that Bex+Flu should have a distinct edge on the side-effect front. It's sure is nice to see some ca treatments where people continue to improve after treatment instead of immediately resuming their downward progress. This race isn't over yet by any means, but this sure looks like encouraging data for CLTR, and vindication for V1's belief in Bex. I still have the CLTR Jan 15 calls I picked up when the stock was at 12, and so I'm a happy camper too. Be even happier if the BLA were accepted. Peter

To: Gordon James who wrote (429)	12/5/1999 11:38:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 666

Gordon: Bex responses sometimes take many months to complete I'm presuming that, as far as "tranformed cell load" is concerned, that the responses are completed early, but that it just takes time for patient appearance (node architecture, etc.) to catch up? Or is an issue of damaged cells that are not replication-competent sitting around and making it look like the patient isn't CR when they actually are? Can you find some brains to pick regarding what's happening in the interval 3-6 months followup? Apologize if I'm asking naive questions that have been addressed previously. Staying on the "naive" front.... why were 24 patients non-evaluable? I am starting to believe that we will find Bex+Flu to be superior to Rit+CHOP in term of safety profile as well That would win the day. That would win the day. That would win the day! gotta get some shuteye now! I'm adding to the chorus of "thank yous", big-time. Rick